ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1865

Identification of Parameters Associated with a Diagnostic Delay in Axial Spondyloarthritis:Results from the European Map of Axial Spondyloarthritis (EMAS)

Marco Garrido-Cumbrera1, Victoria Navarro-Compán2, Christine Bundy3, Raj Mahapatra4, Souzi Makri5, José Correa-Fernández6, Laura Christen7, Carlos-Jesus Delgado-Domínguez8 and Denis Poddubnyy9, 1Health & Territory Research (HTR), Universidad de Sevilla / Spanish Federation of Spondyloarthritis Associations, Sevilla, Spain, 2Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, 3Cardiff University, Cardiff, United Kingdom, 4Axial Spondyloarthritis International Federation, London, United Kingdom, 5Cyprus League Against Rheumatism, Nicosia, Cyprus, 6Health & Territory Research (HTR), Universidad de Sevilla, Sevilla, Spain, 7Novartis Pharma AG, Basel, Switzerland, 8Health & Territory Research, Seville, Spain, 9Charité – Universitätsmedizin Berlin, Berlin, Germany

Meeting: ACR Convergence 2020

Keywords: spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: Axial SpA

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Early diagnosis of Axial Spondyloarthritis (axSpA) is crucial for timely access to specialist care and effective treatment. The aim is to assess the current diagnostic delay in axSpA and identify the parameters associated with increased diagnostic delay in a European sample.

Methods: Data from unselected patients participating in the European Map of Axial Spondyloarthritis (EMAS) study through an online survey (2017- 2018) across 13 countries were analysed. Mean differences in diagnostic delay were analysed using Mann-Whitney and Kruskal-Wallis tests, among sociodemographic and disease-related factors. A multivariate linear regression analysis was carried out to identify the relative weight of the associated parameters in determining diagnostic delay.

Results: 2,846 patients participated in EMAS. Mean age was 43.9 years, 61.3% were female, 48.1% had a university degree, and 53.9% were employed. Of the 2846 participants, 2652 provided information for calculating diagnostic delay. Mean age at symptom onset was 26.6 ± 11.1, mean age at diagnosis was 33.7 ± 11.5, and mean diagnostic delay was 7.4 ± 8.4 (Fig. 1). The following variables were associated with longer diagnostic delay in the bivariate analysis: older age, female gender, being diagnosed by a rheumatologist (Table 1). In the multivariate regression analysis younger age at symptom onset, number of HCPs seen before were associated with diagnostic delay (Table 2).

Conclusion: In this large sample of axSpA patients from 13 different European countries, the average diagnostic delay was more than seven years. The fact that one of the most strongly associated parameters to diagnostic delay was number of HCPs seen before diagnosis suggests the need for urgent action to reduce incorrect referrals to shorten the patient journey to diagnosis across Europe.

Figure 1. Average years of diagnostic delay across EMAS countries (N: 2,652)

Table 1. Associations between sociodemographic and disease-related variables and diagnostic delay (N: 2,652)


Disclosure: M. Garrido-Cumbrera, None; V. Navarro-Compán, Novartis Pharma, 1, 5, 8, AbbVie Inc., 5, 8, Eli Lilly and Company, 5, 8, Pfizer Inc., 5, UCB, 5, 8; C. Bundy, Abbvie, 8, Celgene, 8, Janssen, 8, Lilly, 8, Novartis, 8, Pfizer, 8; R. Mahapatra, None; S. Makri, None; J. Correa-Fernández, None; L. Christen, Novartis Pharma AG, 3; C. Delgado-Domínguez, None; D. Poddubnyy, Eli Lilly and Company, 2, 5, 8, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, BioCad, 5, Gilead, 5, GSK, 5, UCB, 5, 8, BMS, 8.

To cite this abstract in AMA style:

Garrido-Cumbrera M, Navarro-Compán V, Bundy C, Mahapatra R, Makri S, Correa-Fernández J, Christen L, Delgado-Domínguez C, Poddubnyy D. Identification of Parameters Associated with a Diagnostic Delay in Axial Spondyloarthritis:Results from the European Map of Axial Spondyloarthritis (EMAS) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/identification-of-parameters-associated-with-a-diagnostic-delay-in-axial-spondyloarthritisresults-from-the-european-map-of-axial-spondyloarthritis-emas/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-parameters-associated-with-a-diagnostic-delay-in-axial-spondyloarthritisresults-from-the-european-map-of-axial-spondyloarthritis-emas/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology